All Posts | Links Medicus - Free Medical News & Perspective

Strengthening the global response to climate change and infectious disease threats

2 Nov, 2020 | 02:29h | UTC

Strengthening the global response to climate change and infectious disease threats – The BMJ

Commentary on Twitter

Climate change is emerging as an important driver of disease incidence. This #BMJInfographic introduces six strategies for intervening in the complex network of connections around climate change and infectious disease @will_s_t https://t.co/5SgFRoJTa9 #virtualWISH2020 @WISHQatar pic.twitter.com/9iOzIJtXLj

— The BMJ (@bmj_latest) November 1, 2020

Cohort study: Risk of hospital admission with Covid-19 in healthcare workers and their households

2 Nov, 2020 | 02:35h | UTC

Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study – The BMJ

Commentaries: High-risk COVID contact puts health workers, patients, families at risk – CIDRAP AND Health workers and their families account for 1 in 6 hospital COVID-19 cases – BMJ

Commentary on Twitter

NEW #BMJResearch Healthcare workers and their families account for 17% of hospital admissions for #COVID19 in the working age population (18-65 years): https://t.co/HsNkpBv2Xl

— The BMJ (@bmj_latest) November 1, 2020

CDC Report: Transmission of SARS-COV-2 infections in households

2 Nov, 2020 | 02:37h | UTC

Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020 – CDC Morbidity and Mortality Weekly Report

Commentaries: A new CDC study suggests roughly 50% of people living with someone who has COVID-19 get it — usually in less than 5 days – Business Insider AND Household spread of Covid-19 is common and quick, a new CDC study finds – CNN

Commentaries on Twitter

New CDC study finds that children pass along Covid to household members just as frequently as adults do. This underscores why it's crucial to contain the virus among all populations. https://t.co/sZHOh1wOG3

— Dr. Tom Frieden (@DrTomFrieden) October 31, 2020

(1/7) Important prospective study of household transmission by CDC, suggesting children and adults are similarly likely to transmit #SARSCoV2. The household secondary attack rate was at least 35%, and 18% of cases were asymptomatic.https://t.co/iEdx2VBPXz pic.twitter.com/mq4LxSoU0J

— Dr Zoë Hyde (@DrZoeHyde) October 31, 2020

Opinion – The evidence is clear: if countries act together, they can suppress Covid

2 Nov, 2020 | 02:27h | UTC

The evidence is clear: if countries act together, they can suppress Covid – The Guardian

The science of superspreading

2 Nov, 2020 | 02:30h | UTC

The science of superspreading – Science

Scientists warn Americans are expecting too much from a vaccine

2 Nov, 2020 | 02:25h | UTC

Scientists Warn Americans Are Expecting Too Much From a Vaccine – Kaiser Health News

Trends in COVID-19 risk-adjusted mortality rates

2 Nov, 2020 | 02:24h | UTC

Trends in COVID-19 Risk-Adjusted Mortality Rates – Journal of Hospital Medicine

Commentary: Study reveals factors that account for reduced death rates from COVID-19 – NYU School of Medicine / News Medical

Commentary on Twitter

Trends in COVID-19 Risk-Adjusted Mortality Rates | Journal of Hospital Medicine: “Data from one health system suggest that mortality from COVID-19 is decreasing even after accounting for patient characteristics.” https://t.co/AtQ6lPnzhQ

— Dr. Ron Daniels BEM (@SepsisUK) October 25, 2020

Can covid-19 help us deal with the pandemic of defensive medicine?

2 Nov, 2020 | 02:28h | UTC

Can covid-19 help us deal with the pandemic of defensive medicine? – The BMJ Opinion

Meta-analysis: Comparison of acetaminophen with ibuprofen for treatment of fever or pain in children younger than 2 years

2 Nov, 2020 | 02:21h | UTC

Comparison of Acetaminophen (Paracetamol) With Ibuprofen for Treatment of Fever or Pain in Children Younger Than 2 Years: A Systematic Review and Meta-analysis – JAMA Network Open

Commentary on Twitter

Systematic review & meta-analysis finds use of ibuprofen vs acetaminophen for the treatment of fever or pain in children <2 years was associated with reduced temperature and less pain within the first 24 hours of treatment, with equivalent safety. https://t.co/Kl08IhwJKN

— JAMA Network Open (@JAMANetworkOpen) October 30, 2020

Influence and management of conflicts of interest in randomized clinical trials: qualitative interview study

2 Nov, 2020 | 02:22h | UTC

Influence and management of conflicts of interest in randomised clinical trials: qualitative interview study – The BMJ

Commentary on Twitter

In a great qualitative interview study @bmj_latest @LasseOstengaard, @AndreasLundh2 & colleagues show some staggering trialist comments on how trial sponsors tried to influence the clinical trials with manipulation, spin and selective reporting https://t.co/KN25JeYErU pic.twitter.com/2leb0OQmCG

— Lars Villads Bennedsen, MD PhD GP (@LarsJorgensenMD) October 30, 2020

Expert analysis: Efficacy and safety of colchicine in patients with chronic stable coronary disease

2 Nov, 2020 | 02:18h | UTC

Efficacy and Safety of Colchicine in Patients With Chronic Stable Coronary Disease – American College of Cardiology

Randomized trial: Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions

2 Nov, 2020 | 02:17h | UTC

Short-Term Topical Tetracaine Is Highly Efficacious for the Treatment of Pain Caused by Corneal Abrasions: A Double-Blind, Randomized Clinical Trial – Annals of Emergency Medicine

Report: COVID-19 infection fatality ratio estimates from seroprevalence

30 Oct, 2020 | 01:16h | UTC

Report 34 – COVID-19 Infection Fatality Ratio Estimates from Seroprevalence – Imperial College London

Full report: COVID-19 Infection Fatality Ratio: Estimates from Seroprevalence

Commentary on Twitter

UPDATE #COVID19 Infection Fatality Ratio (IFR):

➡️1.15% IFR (high income countries)
➡️0.23% IFR (low income countries)
➡️0.1% IFR (under 40 year olds)
➡️5.6% IFR (over 80 year olds)
➡️Risk of COVID19 death doubles every eight years of age

👇Report 34 https://t.co/171hx5LMvp pic.twitter.com/M1rmq673Rf

— MRC Centre for Global Infectious Disease Analysis (@MRC_Outbreak) October 29, 2020

CDC Report: 1 infected camper likely led to 115 coronavirus cases at an overnight camp

30 Oct, 2020 | 01:15h | UTC

1 infected camper likely led to 115 coronavirus cases at an overnight camp where people didn’t have to wear masks or social distance – Business Insider

Original report: COVID-19 Outbreak at an Overnight Summer School Retreat ― Wisconsin, July–August 2020 – CDC Morbidity and Mortality Weekly Report

Commentary on Twitter

When 1 high school student who tested covid negative 1 week prior to a retreat led to 116 cases (76% of the students and staff)https://t.co/vjKImeE4vg @CDCgov

— Eric Topol (@EricTopol) October 29, 2020

Case study: Urinary magnesium in the evaluation of hypomagnesemia

2 Nov, 2020 | 02:19h | UTC

Urinary Magnesium in the Evaluation of Hypomagnesemia – JAMA (free for a limited period)

Perspective: Will SARS-CoV-2 become endemic?

30 Oct, 2020 | 01:12h | UTC

Will SARS-CoV-2 become endemic? – Science

It may be time to reset expectations on when we’ll get a Covid-19 vaccine

30 Oct, 2020 | 01:10h | UTC

It may be time to reset expectations on when we’ll get a Covid-19 vaccine – STAT

The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug

30 Oct, 2020 | 01:14h | UTC

The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug – Science

Commentaries on Twitter

Remdesivir, despite failing in Solidarity trial, received FDA approval without input from outside advisory group. EU cut pricing deal with Gilead without knowing Solidarity data. @kakape and I explain in "The ‘very, very bad look’ of remdesivir" https://t.co/yTKq2A1WQT pic.twitter.com/NhBLum09VG

— Jon Cohen (@sciencecohen) October 28, 2020

Uncovering a scandal about Gilead and Remdesivir
Deep reporting by @sciencecohen and @kakape @ScienceMagazine
The company knew the #SOLIDARITY trial data well before it its preprint. And so did the FDA before giving a full approval, w/o external review https://t.co/4REMEwTvc5

— Eric Topol (@EricTopol) October 28, 2020